Financial Metrics Unveiled: Allogene Therapeutics Inc (ALLO)’s Key Ratios in the Spotlight

Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The price of Allogene Therapeutics Inc (NASDAQ: ALLO) closed at $2.84 in the last session, up 5.58% from day before closing price of $2.69. In other words, the price has increased by $5.58 from its previous closing price. On the day, 1.09 million shares were traded. ALLO stock price reached its highest trading level at $2.86 during the session, while it also had its lowest trading level at $2.71.

Ratios:

We take a closer look at ALLO’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 12.25 and its Current Ratio is at 12.25. In the meantime, Its Debt-to-Equity ratio is 0.18 whereas as Long-Term Debt/Eq ratio is at 0.17.

On May 31, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $11.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 21 ’24 when Douglas Earl Martin bought 28,310 shares for $2.79 per share.

MESSEMER DEBORAH M. sold 18,641 shares of ALLO for $42,488 on Jun 18 ’24. The Director now owns 166,765 shares after completing the transaction at $2.28 per share. On May 30 ’24, another insider, Humer Franz B, who serves as the Director of the company, sold 11,200 shares for $2.34 each. As a result, the insider received 26,181 and left with 255,253 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ALLO now has a Market Capitalization of 593878080 and an Enterprise Value of 243458704. For the stock, the TTM Price-to-Sale (P/S) ratio is 6598.58 while its Price-to-Book (P/B) ratio in mrq is 1.15. Its current Enterprise Value per Revenue stands at 3745.519 whereas that against EBITDA is -0.949.

Stock Price History:

Over the past 52 weeks, ALLO has reached a high of $5.78, while it has fallen to a 52-week low of $2.01. The 50-Day Moving Average of the stock is 7.28%, while the 200-Day Moving Average is calculated to be -11.45%.

Shares Statistics:

According to the various share statistics, ALLO traded on average about 1.87M shares per day over the past 3-months and 1285150 shares per day over the past 10 days. A total of 167.13M shares are outstanding, with a floating share count of 136.57M. Insiders hold about 34.69% of the company’s shares, while institutions hold 66.86% stake in the company. Shares short for ALLO as of 1727654400 were 38512665 with a Short Ratio of 20.63, compared to 1724976000 on 38940757. Therefore, it implies a Short% of Shares Outstanding of 38512665 and a Short% of Float of 25.919999999999998.

Most Popular